Compare Old Dominion Freight Line Inc (ODFL) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Old Dominion Freight Line Inc vs Sana Biotechnology Inc — how do they compare? Old Dominion Freight Line Inc trades at $181.97 (market cap $37.68B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: Old Dominion Freight Line Inc is far larger — about 45× Sana Biotechnology Inc's market cap, and Old Dominion Freight Line Inc pays a 0.64% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Old Dominion Freight Line Inc for 76 Days and Sana Biotechnology Inc for 23 Days on average.
| ODFL | SANA | |
|---|---|---|
Market Cap | $37.68B | $836.71M |
Volume | 1,550,104 | 4,507,444 |
Sector | Industrials | Health |
52-Week High | $248.73 | $5.92 |
52-Week Low | $126.29 | $2.68 |
Typical Hold Time | 76 Days | 23 Days |
Enterprise Value | $37.42B | $749.96M |
Dividend Yield | 0.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ODFL trades at $181.65, up 3.44% today, with strong recent earnings beats and a 4.9% general rate increase effective October 5, 2026, to counter rising costs. The stock shows robust fundamentals with a 19.44% net income margin and 24.82% ROE, though valuation ratios like P/E of 34.95 are elevated. Technical indicators are bearish overall, with support at $180 and resistance at $183, while analyst consensus is mixed with a $230.93 price target.
Outlook: ODFL's consistent earnings outperformance and strategic rate hikes support growth, but high valuation and bearish technical signals pose near-term risks. Investors should weigh solid profitability against potential volatility from freight market fluctuations and competitive pressures.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent news highlights multiple investor conference presentations and ongoing legal scrutiny regarding fiduciary duties.
Despite strong analyst support (82% buy ratings), SANA's lack of revenue generation and negative profitability metrics present substantial investment risk. The company's cash flow remains negative, requiring continued financing. Near-term catalysts include upcoming Q3 earnings and clinical developments, but investors should weigh the high-risk profile against potential long-term biotechnology breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Old Dominion Freight Line Inc
Old Dominion Freight Line is the fourth-largest less-than-truckload carrier in the United States, with more than 240 service centers and 9,200-plus tractors. OD is by far one of the most disciplined and efficient providers in the trucking industry, and its profitability and capital returns stand head and shoulders above its peers. Strategic initiatives revolve around increasing network density through market share gains and maintaining industry-leading service via consistent infrastructure investment.
Read more on ODFL →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
